These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 27571060)

  • 1. Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
    Rodi M; Dimisianos N; de Lastic AL; Sakellaraki P; Deraos G; Matsoukas J; Papathanasopoulos P; Mouzaki A
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27571060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The T-cell pool is anergized in patients with multiple sclerosis in remission.
    Fransson ME; Liljenfeldt LS; Fagius J; Tötterman TH; Loskog AS
    Immunology; 2009 Jan; 126(1):92-101. PubMed ID: 18624727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children.
    Horellou P; de Chalus A; Giorgi L; Leroy C; Chrétien P; Hacein-Bey-Abina S; Bourgeois C; Mariette X; Serguera C; Le Grand R; Deiva K
    Front Immunol; 2021; 12():679770. PubMed ID: 34220827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.
    Harp CT; Ireland S; Davis LS; Remington G; Cassidy B; Cravens PD; Stuve O; Lovett-Racke AE; Eagar TN; Greenberg BM; Racke MK; Cowell LG; Karandikar NJ; Frohman EM; Monson NL
    Eur J Immunol; 2010 Oct; 40(10):2942-56. PubMed ID: 20812237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.
    Burman J; Fransson M; Tötterman TH; Fagius J; Mangsbo SM; Loskog AS
    Immunology; 2013 Oct; 140(2):211-9. PubMed ID: 23721329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
    Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
    Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.
    Haas J; Hug A; Viehöver A; Fritzsching B; Falk CS; Filser A; Vetter T; Milkova L; Korporal M; Fritz B; Storch-Hagenlocher B; Krammer PH; Suri-Payer E; Wildemann B
    Eur J Immunol; 2005 Nov; 35(11):3343-52. PubMed ID: 16206232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse.
    Sáez-Torres I; Brieva L; Espejo C; Barrau MA; Montalban X; Martínez-Caceres EM
    Autoimmunity; 2002 Feb; 35(1):45-50. PubMed ID: 11908706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Galazka G; Mycko MP; Selmaj I; Raine CS; Selmaj KW
    Mult Scler; 2018 Apr; 24(4):449-458. PubMed ID: 28273783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
    Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
    FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
    Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
    J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant forms of myelin antigens expressed on Chinese hamster ovary (CHO) cells as a tool for identification of autoantibodies in serum of multiple sclerosis patients.
    Jaśkiewicz E; Michałowska-Wender G; Pyszczek A; Wender M
    Folia Neuropathol; 2010; 48(1):45-8. PubMed ID: 20383810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis.
    Skundric DS; Cruikshank WW; Drulovic J
    J Neuroinflammation; 2015 Apr; 12():78. PubMed ID: 25896927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelin oligodendrocyte glycoprotein revisited-sensitive detection of MOG-specific T-cells in multiple sclerosis.
    Bronge M; Ruhrmann S; Carvalho-Queiroz C; Nilsson OB; Kaiser A; Holmgren E; Macrini C; Winklmeier S; Meinl E; Brundin L; Khademi M; Olsson T; Gafvelin G; Grönlund H
    J Autoimmun; 2019 Aug; 102():38-49. PubMed ID: 31054941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity.
    Hellings N; Gelin G; Medaer R; Bruckers L; Palmers Y; Raus J; Stinissen P
    J Neuroimmunol; 2002 May; 126(1-2):143-60. PubMed ID: 12020966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Caggiula M; Marti A; Sancricca C; Angelucci F; Mirabella M; Tonali PA; Batocchi AP
    Immunology; 2009 Jul; 127(3):418-28. PubMed ID: 19016907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.